Loading...
Market
Which type of bacterial infection will PS757 be used to treat by August 5, 2025?
2
Resolution / Starting Odds
Flesh-eating bacteria • 25%
MRSA • 25%
Pneumonia • 25%
Other • 25%
Medical journals and official press releases
Story
New Compound PS757 Fights Drug-Resistant Bacteria, Guides GmPcide Development
Aug 5, 2024, 07:05 AM
Researchers have discovered a new compound, PS757, that shows promise in fighting flesh-eating and other drug-resistant bacteria. This revolutionary dual-action antibiotic makes bacterial resistance nearly impossible by damaging the cell membranes of the bacteria. The findings, which were tested on Gram-positive pathogens in mice, are expected to guide the development and optimization of a new class of antibiotics called GmPcide compounds. The discovery was announced on August 4 and further detailed on August 5.
View original story
Similar markets
Gut microbiome • 25%
Skin microbiome • 25%
Oral microbiome • 25%
Other • 25%
Yes • 50%
No • 50%
Gut microbiome • 25%
Skin microbiome • 25%
Oral microbiome • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
GSK • 25%
Other • 25%
Salmonella • 25%
Campylobacter • 25%
E. coli • 25%
Other • 25%
Yes • 50%
No • 50%
1-3 strains • 33%
4-6 strains • 33%
More than 6 strains • 33%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
HIV • 25%
Hepatitis B • 25%
Hepatitis C • 25%
None • 25%